David F. Archer

13.7k total citations · 1 hit paper
312 papers, 9.2k citations indexed

About

David F. Archer is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Reproductive Medicine. According to data from OpenAlex, David F. Archer has authored 312 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Endocrinology, Diabetes and Metabolism, 114 papers in Genetics and 110 papers in Reproductive Medicine. Recurrent topics in David F. Archer's work include Estrogen and related hormone effects (111 papers), Menopause: Health Impacts and Treatments (103 papers) and Reproductive Health and Contraception (76 papers). David F. Archer is often cited by papers focused on Estrogen and related hormone effects (111 papers), Menopause: Health Impacts and Treatments (103 papers) and Reproductive Health and Contraception (76 papers). David F. Archer collaborates with scholars based in United States, Canada and United Kingdom. David F. Archer's co-authors include James H. Pickar, Ginger D. Constantine, Sebastián Mirkin, Fernand Labrie, Peter U. Clark, Joel D. Blum, J. A. Rial, Alan C Mix, David Pollard and Nicklas G. Pisias and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

David F. Archer

307 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The middle Pleistocene transition: characteristics, mechanisms, and implications for long-term changes in atmospheric pCO2

2006 834 citations David F. Archer et al. profile →

Peers

Countries citing papers authored by David F. Archer

Since Specialization

Citations

This map shows the geographic impact of David F. Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David F. Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David F. Archer more than expected).

Fields of papers citing papers by David F. Archer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David F. Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David F. Archer. The network helps show where David F. Archer may publish in the future.

Co-authorship network of co-authors of David F. Archer

This figure shows the co-authorship network connecting the top 25 collaborators of David F. Archer. A scholar is included among the top collaborators of David F. Archer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David F. Archer. David F. Archer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of estrogens and selective estrogen receptor modulators (SERMs) used for menopausal hormone therapy 2025 ·Menopause The Journal of The North American Menopause Society ·Frank Z. Stanczyk, (unknown), Herjan J.T. Coelingh Bennink, Intira Sriprasert, Sharon A. Winer, Jean‐Michel Foidart, David F. Archer	1
2	Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial 2024 ·BMJ Sexual & Reproductive Health ·Alison Edelman, Jon D. Hennebold, (unknown), Jeong Youn Lim, Ganesh Cherala, Steven W. Blue, (unknown), David W. Erikson, David F. Archer, (unknown)	4
3	A systematic review of the plasminogen activator system in the endometrium and its role in menstruation and abnormal uterine bleeding 2022 ·(unknown), (unknown), (unknown), (unknown), (unknown), Jaime Blanck, David F. Archer, James H. Segars	0
4	Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model 2022 ·PLoS ONE ·Frank Z. Stanczyk, David F. Archer, Lauren Lohmer, Jason R. Pirone, Michelle L. Previtera, Paul Körner	3
5	Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results 2021 ·Contraception ·Mitchell D. Creinin, Carolyn Westhoff, Céline Bouchard, Melissa J. Chen, Jeffrey T. Jensen, Andrew M. Kaunitz, Sharon L. Achilles, Jean-Michel Foidart, David F. Archer	46
6	Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas 2020 ·Obstetrical & Gynecological Survey ·James A. Simon, Ayman Al‐Hendy, David F. Archer, Kurt T. Barnhart, D.A. Bradley, Bruce R. Carr, Thomas Dayspring, Eve C. Feinberg, (unknown), (unknown), Jinhee Kim, Ran Liu, Charlotte D. Owens, Ozgul Muneyyirci‐Delale, Alice Wang, Nelson B. Watts, William D. Schlaff	2
7	TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women 2019 ·Climacteric ·James A. Simon, Risa Kagan, David F. Archer, Ginger D. Constantine, Brian Bernick, (unknown), Sebastián Mirkin	8
8	Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause 2018 ·Menopause The Journal of The North American Menopause Society ·Fernand Labrie, David F. Archer, William Koltun, (unknown), Douglas Young, Louise Frenette, David Portman, Marlene Montesino, Isabelle Côté, Julie Parent, Lyne Lavoie, (unknown), Céline Martel, Mario Vaillancourt, John Balser, Érick Moyneur	68
9	The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review 2018 ·Menopause The Journal of The North American Menopause Society ·James A. Simon, Irwin Goldstein, Noel N. Kim, Susan R. Davis, Susan Kellogg‐Spadt, Lior Löwenstein, JoAnn V. Pinkerton, Cynthia A. Stuenkel, Abdulmaged M. Traish, David F. Archer, Gloria Bachmann, Andrew T. Goldstein, Rossella E. Nappi, Linda Vignozzi	94
10	A 17β-Estradiol–Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial 2018 ·Obstetrical & Gynecological Survey ·Rogerio A. Løbo, David F. Archer, Risa Kagan, Andrew M. Kaunitz, Ginger D. Constantine, James H. Pickar, Shelli Graham, Brian Bernick, Sebastián Mirkin	2
11	Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas 2018 ·Obstetrics and Gynecology ·Bruce R. Carr, Elizabeth A. Stewart, David F. Archer, Ayman Al‐Hendy, D.A. Bradley, Nelson B. Watts, Michael P. Diamond, (unknown), Charlotte D. Owens, Kristof Chwalisż, W. Rachel Duan, Ahmed M. Soliman, (unknown), James A. Simon	54
12	A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom 2017 ·Menopause The Journal of The North American Menopause Society ·Robin Kroll, David F. Archer, Yu‐Hua Lin, Vilma Sniukiene, James Liu	29
13	Heavy menstrual bleeding diagnosis and medical management 2017 ·SHILAP Revista de lepidopterología ·Intira Sriprasert, (unknown), Thomas Kimble, David F. Archer	45
14	Assessment of the vaginal residence time of biomarkers of semen exposure 2016 ·Contraception ·Andrea R. Thurman, Terry A. Jacot, Johan H. Melendez, Thomas Kimble, Margaret Christine Snead, Roxanne Jamshidi, (unknown), David F. Archer, Gustavo F. Doncel, Christine K. Mauck	16
15	A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women 2015 ·Contraception ·Anh Dinh, Intira Sriprasert, Alistair Williams, David F. Archer	49
16	Contraceptive Efficacy, Safety, Fit, and Acceptability of a Single-Size Diaphragm Developed With End-User Input 2015 ·Obstetrics and Gynecology ·Jill L. Schwartz, Debra H. Weiner, (unknown), Ron G. Frezieres, Mitchell D. Creinin, David F. Archer, Lynn Bradley, Kurt T. Barnhart, Alfred N. Poindexter, Maggie Kilbourne‐Brook, Marianne M. Callahan, Christine Mauck	23
17	Low-Dose Levonorgestrel and Ethinyl Estradiol Patch and Pill 2014 ·Obstetrics and Gynecology ·Andrew M. Kaunitz, David Portman, Carolyn Westhoff, David F. Archer, Daniel R. Mishell, Arkady Rubin, Marie L. Foegh	16
18	Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health 2013 ·Climacteric ·T. J. de Villiers, Amos Pines, Nick Panay, Marco Gambacciani, David F. Archer, Rod Baber, Susan R. Davis, Anne Gompel, Victor W. Henderson, Róbert Langer, Roger A. Lobo, Geneviève Plu‐Bureau, David Sturdee, (unknown)	204
19	Norethindrone Acetate 1.0 Milligram and Ethinyl Estradiol 10 Micrograms as an Ultra Low-Dose Oral Contraceptive 2013 ·Obstetrics and Gynecology ·David F. Archer, Steven T. Nakajima, (unknown), (unknown), (unknown), William Koltun, R. D. Gilbert, Herman Ellman	25
20	Contraceptive Efficacy, Acceptability, and Safety of C31G and Nonoxynol-9 Spermicidal Gels 2010 ·Obstetrics and Gynecology ·Anne E. Burke, Kurt T. Barnhart, Jeffrey T. Jensen, Mitchell D. Creinin, Terri Walsh, Livia Wan, Carolyn Westhoff, Michael A. Thomas, David F. Archer, (unknown), James Liu, William D. Schlaff, Bruce R. Carr, Diana Blithe	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact